A number of previous studies have described alterations in serglycin in different tumors [44–46], and it is also worth noting that results analogous to those described in this work, involving both downregulation of transcription and reduction in the population of mast cells, have also been obtained in RSCRCs [21], suggesting that this is a common feature of both CRC types. Here, SRGN is linked to colorectal carcinoma.